---
title: "BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299889967.md"
description: "BMO Capital analyst Evan Seigerman reiterated a Buy rating on Vertex Pharmaceuticals (VRTX) with a $600 price target. This follows a similar Buy from Barclays, while Canaccord Genuity maintained a Hold rating."
datetime: "2026-09-23T11:35:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299889967.md)
  - [en](https://longbridge.com/en/news/299889967.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299889967.md)
generator: "portal-rs"
---

# BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX)

BMO Capital analyst Evan Seigerman reiterated a Buy rating on Vertex Pharmaceuticals today and set a price target of $600.00.

According to TipRanks, Seigerman is a 5-star analyst with an average return of 10.9% and a 57.95% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Amgen, and Eli Lilly & Co.

In addition to BMO Capital, Vertex Pharmaceuticals also received a Buy from Barclays’s Eliana Merle in a report issued today. However, on the same day, Canaccord Genuity maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [BMO.US](https://longbridge.com/en/quote/BMO.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [2 Healthcare Stocks That Just Delivered Great News for Investors](https://longbridge.com/en/news/300206760.md)
- [Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug](https://longbridge.com/en/news/299800601.md)
- [Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria](https://longbridge.com/en/news/299770014.md)
- [Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuria](https://longbridge.com/en/news/299762830.md)
- [Are Wall Street Analysts Bullish on Vertex Stock?](https://longbridge.com/en/news/296449653.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**